After Hemophilia Deal, UniQure Sees Zolgensma As Model For Huntington’s Gene Therapy
Focused On Long-Term Gene Therapy Leadership
Executive Summary
While M&A-hungry investors were disappointed in no sale, uniQure now aims to pivot toward Huntington’s – and sees Zolgensma as an example to follow.
You may also be interested in...
UniQure Expects To Resolve FDA Clinical Hold Within Three Months
The gene therapy EtranaDez for hemophilia B placed on clinical hold after a patient was diagnosed with liver cancer, but UniQure points to that patient’s extensive history of liver disease.
Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed
Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.